Role of HER2 gene overexpression in breast carcinoma

Journal of Cellular Physiology

Volumn 182, Issue 2, 2000, Pages 150-162

  Ménard, Sylvie ^a   Tagliabue, Elda ^a   Campiglio, Manuela ^a   Pupa, Serenella M ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EMODIN; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; ETOPOSIDE; FLUOROURACIL; GLYCOPROTEIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GROWTH INHIBITOR; HORMONE; INTERLEUKIN 12; INTERLEUKIN 2; LIPOSOME; MELPHALAN; MEMBRANE PROTEIN; METHOTREXATE; MONOCLONAL ANTIBODY; NEU DIFFERENTIATION FACTOR; PACLITAXEL; PEPTIDE DERIVATIVE; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; RADIOISOTOPE; TAMOXIFEN; TAXANE DERIVATIVE; TOXIN; TRASTUZUMAB; UNINDEXED DRUG;

BREAST CARCINOMA; CELL TRANSFORMATION; DRUG SENSITIVITY; GENE ACTIVATION; GENE AMPLIFICATION; GENE OVEREXPRESSION; HORMONAL THERAPY; HUMAN; NONHUMAN; ONCOGENE NEU; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SIGNAL TRANSDUCTION;

BREAST NEOPLASMS; CARCINOMA; FEMALE; FORECASTING; GENE AMPLIFICATION; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, ERBB-2; HUMANS; PROGNOSIS;

EID: 0242455889     PISSN: 00219541     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-4652(200002)182:2<150::AID-JCP3>3.0.CO;2-E     Document Type: Review

References (181)

1. Adam L, Vadlamudi R, Kondapaka SB, Chernoff J, Mendelsohn J, Kumar R. 1998. Heregulin regulates cytoskeletal reorganization and cell migration through the p21-activated kinase-1 via phosphatidylinositol-3 kinase. J Biol Chem 273:28238-28246.
2. Adams GP, Schier R, McCall AM, Crawford RS, Wolf EJ, Weiner LM, Marks JD. 1998. Prolonged in vivo tumour retention of a human diabody targeting the extracellular domain of human HER2/neu. Br J Cancer 77:1405-1412.
3. Adnane J, Gaudray P, Simon MP, Simony-Lafontaine J, Jeanteur P, Theillet C. 1989. Proto-oncogene amplification and breast tumor phenotype. Oncogene 4:1389-1395.
4. Ali IU, Campbell G, Lidereau R, Callahan R. 1988. Lack of evidence for the prognostic significance of c-erbB-2 amplification in human breast carcinoma. Oncogene Res 3:139-146.
5. Allred DC, Clark GM, Tandon AK, Molina R, Tormey DC, Osborne CK, Gilchrist KW, Mansour EG, Abeloff M, Eudey L, McGuire WL. 1992. HER2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma. J Clin Oncol 10:599-605.
6. Antoniotti S, Maggiora P, Dati C, De Bortoli M. 1992. Tamoxifen up-regulates c-erb B-2 expression in oestrogen-responsive breast cancer cells in vitro. Eur J Cancer 28:318-321.
7. Arguello F, Baggs RB, Eskenazi AE, Duerst RE, Frantz CN. 1991. Vascular anatomy and organ-specific tumor growth as critical factors in the development of metastases and their distribution among organs. Int J Cancer 48:583-590.
8. Babiak J, Hugh J, Poppema S. 1992. Significance of c-erb B-2 amplification and DNA aneuploidy: analysis in 78 patients with node-negative breast cancer. Cancer 70:770-776.
9. Bacus SS, Chin D, Yarden Y, Zelnick CR, Stern DF. 1996a. Type 1 receptor tyrosine kinases are differentially phosphorylated in mammary carcinoma and differentially associated with steroid receptors. Am J Pathol 148:549-558.
10. Bacus SS, Yarden Y, Oren M, Chin DM, Lyass L, Zelnick CR, Kazarov A, Toyofuku W, Gray-Bablin J, Beerli RR, Hynes NE, Nikiforov M, Haffner R, Gudkov A, Keyomarsi K. 1996b. Neu differentiation factor (Heregulin) activates a p53-dependent pathway in cancer cells. Oncogene 12:2535-2547.
11. neu/erbB-2 and the epidermal growth factor receptor. Proc Natl Acad Sci USA 89:11637-11641.
12. Bargmann CI, Hung M-C, Weinberg RA. 1986. The neu oncogene encodes an epidermal-growth-factor receptor-related protein. Nature 319:226-230.
13. Baselga J, Norton L, Albanell J, Kim Y M, Mendelsohn J. 1998. Recombinant humanized anti-HER2 antibody (Herceptin TM) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res 58:2825-2831.
14. Baselga J, Seidman A D, Rosen PP, Norton L. 1997. HER2 overexpression and paclitaxel sensitivity in breast cancer: therapeutic implications. Oncology 11:43-48.
15. HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 14:737-744.
16. Battifora H, Gaffey MJ, Esteban J, Mehta P, Bailey A, Faucett C, Niland J. 1991. Immunohistochemical assay of neu/c-erbB-2 oncogene product in paraffin-embedded tissues in early breast cancer: retrospective follow-up study of 245 stage I and II cases. Mod Pathol 4:466-474.
17. Baulida J, Kraus MH, Alimandi M, Di Fiore PP, Carpenter G. 1996. All ErbB receptors other than the epidermal growth factor receptor are endocytosis impaired. J Biol Chem 271:5251-5257.
18. Beerli RR, Graus-Porta D, Woods-Cook K, Chen XM, Yarden Y, Hynes NE. 1995. Neu differentiation factor activation of ErbB-3 and ErbB-4 is cell specific and displays a differential requirement for ErbB-2. Mol Cell Biol 15:6496-6505.
19. Beerli R R, Weis W, Hynes N E. 1994. Intracellular expression of single chain antibodies reverts ErbB-2 transformation. J Biol Chem 269:23931-23936.
20. Benz CC, Scott GK, Sarup JC. 1992. Estrogen-dependent, tamoxifenresistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res Treat 24:85-89.
21. Berger MS, Locher GW, Saurer S, Gullick WJ, Waterfield MD, Groner B, Hynes ME. 1988. Correlation of c erb B-2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading. Cancer Res 48:1238-1243.
22. Bianchi S, Paglierani M, Zampi G, Cardona G, Cataliotti L, Bonardi R, Ciatto S. 1993. Prognostic significance of c-erbB-2 expression in node negative breast cancer. Br J Cancer 67:625-629.
23. Borg A, Tandon A K, Sigurdsson H, Clark G M, Ferno M, Fuqua S A, Killander D, McGuire WL. 1990. HER2/neu amplification predicts poor survival in node-positive breast cancer. Cancer Res 50:4332-4337.
24. Borg Å, Baldetorp B, Fernö M, Killander D, Olsson H, Sigurdsson H. 1991. ERBB2 amplification in breast cancer with a high rate of proliferation. Oncogene 6:137-143.
25. Borg Å, Tandon AK, Sigurdsson H, Clark GM, Ferno M, Fuqua SA, Killander D, McGuire WL. 1990. HER-2/neu amplification predicts poor survival in node-positive breast cancer. Cancer Res 50:4332-4337.
26. Busmanis I, Feleppa F, Jones A, McGrath KM, Reed R, Collins J, Russell I, Begley CG. 1994. Analysis of cerbB2 expression using a panel of 6 commercially available antibodies. Pathology 26:261-267.
27. Carlomagno C, Perrone F, Gallo C, De Laurentiis M, Lauria R, Morabito A, Pettinato G, Panico L, D'Antonio A, Bianco AR, De Placido S. 1996. c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases. J Clin Oncol 14:2702-2708.
28. Carraway KL III, Cantley LC. 1994. A neu acquaintance for ErbB3 and ErbB4: a role for receptor heterodimerization in growth signaling. Cell 78:5-8.
29. Carraway KL III, Soltoff SP, Diamonti AJ, Cantley LC. 1995. Heregulin stimulates mitogenesis and phosphatidylinositol 3-kinase in mouse fibroblasts transfected with erbB2/neu and erbB3. J Biol Chem 270:7111-7116.
30. Carraway KL III, Weber JL, Unger MJ, Ledesma J, Yu N, Gassmann M, Lai C. 1997. Neuregulin-2, a new ligand of ErbB3/ErbB4-receptor tyrosine kinases. Nature 387:512-516.
31. HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA 89:4285-4289.
32. Charpin C, Garcia S, Bouvier C, Martini F, Lavaut MN, Allasia C, Bonnier P, Andrac L. 1997. c-erbB-2 oncoprotein detected by automated quantitative immunocytochemistry in breast carcinomas correlates with patients' overall and disease-free survival. Br J Cancer 75:1667-1673.
33. Chung J, Grammer TC, Lemon KP, Kazlauskas A, Blenis J. 1994. PDGF- and insulin-dependent pp70S6k activation mediated by phosphatidylinositol-3-OH kinase. Nature 370:71-75.
34. Clark GM. 1998. Should selection of adjuvant chemotherapy for patients with breast cancer be based on erbB-2 status? J Natl Cancer Inst 90:1320-1321.
35. Clark G M, McGuire W L. 1991. Follow-up study of HER-2/neu amplification in primary breast cancer. Cancer Res 51:944-948.
36. Cline MJ, Battifora H, Yokota J. 1987. Proto-oncogene abnormalities in human breast cancer: correlations with anatomic features and clinical course of disease. J Clin Oncol 5:999-1006.
37. Collan Y, Haapasalo H. 1991. The value of mitotic counting in the assessment of prognosis and proliferation in human tumours. J Pathol 163:361-362.
38. Colnaghi MI, Farante GE, Canevari S, Salvadori B, Ménard S. 1987. Los anticuerpos monoclonales en oncologia. Nueva esperanza para un problema no resuelto. Medicina 47:667-672.
39. Corvera S, Czech MP. 1998. Direct targets of phosphoinositide 3-kinase products in membrane traffic and signal transduction. Trends Cell Biol 8:442-446.
40. Daly JM, Olayioye MA, Wong AM, Neve R, Lane HA, Maurer FG, Hynes NE. 1999. NDF/heregulin-induced cell cycle changes and apoptosis in breast tumour cells: role of PI3 kinase and p38 MAP kinase pathways. Oncogene 18:3440-3451.
41. Dati C, Antoniotti S, Taverna D, Perroteau I, De Bortoli M. 1990. Inhibition of c-erbB-2 oncogene expression by estrogens in human breast cancer cells. Oncogene 5:1001-1006.
42. Deo YM, Granziano RF, Repp R, van de Winkel JG. 1997. Clinical significance of IgG Fc receptors and Fc gamma R-directed immunotherapies. Immunol Today 18:127-135.
43. Depowski PL, Brien TPSCE. 1999. Prognostic significance of p34cdc2 cyclin dependent kinase and MIB1 overexpression, and HER-2/neu gene amplification detected by fluorescence in-situ hybridization in breast cancer. Mod Pathol 1998:18A.
44. Deshane J, Siegal GP, Alvarez RD, Wang MH, Feng M, Cabrera G, Liu T, Kay M, Curiel DT. 1996. Targeted tumor killing via an intracellular antibody against erbB-2. J Clin Invest 96:2980-2985.
45. Di Fiore PP, Pierce JH, Kraus MH, Segatto O, King CR, Aaronson SA. 1987. erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. Science 237:178-182.
46. Disis ML, Calenoff E, McLaughlin G, Murphy AE, Chen W, Groner B, Jeschke M, Lydon N, McGlynn E, Livingston RB, Moe R, Cheever MA. 1994. Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer. Cancer Res 54:16-20.
47. Disis ML, Cheever MA. 1997. HER-2/neu protein: a target for antigen-specific immunotherapy of human cancer. Adv Cancer Res 71:343-371.
48. Disis ML, Pupa SM, Gralow JR, Dittadi R, Ménard S, Cheever MA. 1997. High titer HER-2/neu protein specific antibody immunity can be detected in patients with early stage breast cancer. J Clin Oncol 15:3363-3367.
49. Dittadi R, Brazzale A, Pappagallo G, Salbe C, Nascimben O, Rosabian A, Gion M. 1997. ErbB2 assay in breast cancer: possibly improved clinical information using a quantitative method. Anticancer Res 17:1245-1247.
50. Dykens R, Corbett I P, Henry J. 1991. Long term survival in breast cancer related to overexpression of the c-erbB-2 oncoprotein: an immunohistochemical study using monoclonal antibody NCL-CB11. J Pathol 163:105-110.
51. Eissa S, Khalifa A, el-Gharib A, Salah N, Mohamed MK. 1997. Multivariate analysis of DNA ploidy, p53, c-erbB-2 proteins, EGFR, and steroid hormone receptors for short-term prognosis in breast cancer. Anticancer Res 17:3091-3097.
52. Epstein RJ, Druker BJ, Roberts TM, Stiles CD. 1992. Synthetic phosphopeptide immunogens yield activation-specific antibodies to the c-erbB-2 receptor. Proc Natl Acad Sci USA 89:10435-10439.
53. Fernandez AM, Farina GJ, Arangoncillo BP. 1997. Immunohistochemical expression of p53 and c-erbB-2 in breast carcinoma: relation with epidemiologic factors, histologic features and prognosis. Gen Diagn Pathol 142:289-296.
54. Fisk B, Blevins TL, Wharton JT, Ioannides CG. 1995. Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines. J Exp Med 181:2109-2118.
55. Giai M, Roagna R, Ponzone R, De Bortoli M, Dati C, Sismondi P. 1994. Prognostic and predictive relevance of c-erbB-2 and ras expression in node positive and negative breast cancer. Anticancer Res 14: 1441-1450.
56. Giani C, Casalini P, Pupa SM, De Vecchi R, Ardini E, Colnaghi MI, Giordano A, Ménard S. 1998. Increased expression of c-erbB-2 in hormone-dependent breast cancer cells inhibits cell growth and induces differentiation. Oncogene 17:425-432.
57. Goldfarb M, Deed R, MacAllan D, Walther W, Dickson C, Peters G. 1991. Cell transformation by Int-2: a member of the fibroblast growth factor family. Oncogene 6:65-71.
58. Goldman R, Benlevy R, Peles E, Yarden Y. 1990. Heterodimerization of the erbB-1 and erbB-2 receptors in human breast carcinoma cells: a mechanism for receptor transregulation. Biochemistry 29:11024-11028.
59. Graus-Porta D, Beerli RR, Daly JM, Hynes NE. 1997. ErbB-2, the preferred heterodimerization partner of all ErbB receptor, is a mediator of lateral signaling. EMBO J 16:1647-1655.
60. Graus-Porta D, Beerli RR, Hynes NE. 1995. Single-chain antibody-mediated intracellular retention of ErbB-2 impairs Neu differentiation factor and epidermal growth factor signaling. Mol Cell Biol 15:1182-1191.
61. Groenen LC, Nice EC, Burgess AW. 1994. Structure-function relationships for the EGF/TGF-alpha family of mitogens. Growth Factors 11:235-257.
62. Grunt TW, Saceda M, Martin MB, Lupu R, Dittrich E, Krupitza G, Harant H, Huber H, Dittrich C. 1995. Bidirectional interactions between the estrogen receptor and the c-erbB-2 signaling pathways: heregulin inhibits estrogenic effects in breast cancer cells. Int J Cancer 63:560-567.
63. Guerin M, Barrois M, Terrier M J, Spielmann M, Riou G. 1988. Overexpression of either c-myc or c-erbB-2/neu proto-oncogenes in human breast carcinomas: correlation with poor prognosis. Oncogene Res 3:21-31.
64. Guerin M, Gabillot M, Mathieu MC, Travagli JP, Spielmann M, Andrieu N, Riou G. 1989. Structure and expression of c-erbB-2 and EGF receptor genes in inflammatory and non-inflammatory breast cancer: prognostic significance. Int J Cancer 43:201-208.
65. Gullick WJ, Love SB, Wright C, Barnes DM, Gusterson B, Harris A L, Altman D G. 1991. c-erb B-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes. Br J Cancer 63:434-438.
66. Gusterson BA, Gelber RD, Goldhirsch A, Price KN, Säve-Söderborgh J, Anbazhagan R, Styles J, Rudenstam C-M, Golouh R, Reed R, Martinez-Tello F, Tiltman A, Torhorst J, Grigolato P, Bettelheim R, Neville AM, Bürki K, Castiglione M, Collins J, Lindtner J, Senn H-J. 1992. Prognostic importance of c-erb B-2 expression in breast cancer. J Clin Oncol 10:1049-1056.
67. Guy CT, Webster MA, Schaller M, Parsons TJ, Cardiff RD, Muller WJ. 1992. Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc Natl Acad Sci USA 89:10578-10582.
68. Harari D, Tzahar E, Romano J, Shelly M, Pierce J H, Andrews G C, Yarden Y. 1999. Neuregulin-4: a novel growth factor that acts through the ErbB-4 receptor tyrosine kinase. Oncogene 18:2681-2689.
69. Hartmann LC, Ingle JN, Wold LE, Farr GH, Jr, Grill JP, Su JQ, Maihle NJ, Krook JE, Witzig TE, Roche PC. 1994. Prognostic value of c-erb B2 overexpression in axillary lymph node positive breast cancer: results from a randomized adjuvant treatment protocol. Cancer 74:2956-2963.
70. Heintz NH, Leslie KO, Rogers LA, Howard PL. 1990. Amplification of the c-erb B-2 oncogene and prognosis of breast adenocarcinoma. Arch Pathol Lab Med 114:160-163.
71. Hieken TJ, Mehta RR, Shilkaitis A. 1996. HER-2/neu and p53 expression in breast cancer: valid prognostic markers when assessed by direct immunoassay, but not by immunohistochemistry. Proc Annu Meet Am Soc Clin Oncol 15:113.
72. erbB2. Science 256:1205-1210.
73. Horak E, Hartmann F, Garmestani K, Wu C, Brechbiel M, Gansow OA, Landolfi NF, Waldmann TA. 1997. Radioimmunotherapy targeting of HER2/neu oncoprotein on ovarian tumor using lead-212-DOTA-AE1. J Nucl Med 38:1944-1950.
74. Horan T, Wen J, Arakawa T, Liu NL, Brankow D, Hu S, Ratzkin B, Philo JS. 1995. Binding of neu differentiation factor with the extracellular domain of Her2 and Her3. J Biol Chem 270:24604-24608.
75. Hudziak RM, Schlessinger J, Ullrich A. 1987. Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells. Proc Natl Acad Sci USA 84:7159-7163.
76. Jacobs TW, Prioleau JE, Stillman IE, Schnitt SJ. 1996. Loss of tumor marker-immunostaining intensity on stored paraffin slides of breast cancer. J Natl Cancer Inst 88:1054-1059.
77. Jacquemier J, Penault-Llorca F, Viens P, Houvenaeghel G, Hassoun J, Torrente M, Adélaïde J, Birnbaum D. 1994. Breast cancer response to adjuvant chemotherapy in correlation with erb B2 and p53 expression. Anticancer Res 14:2773-2778.
78. Jinno H, Ueda M, Enomoto K, Ikeda T, Kyriakos P, Kitajima M. 1996. Effectiveness of an adriamycin immunoconjugate that recognizes the C-erbB-2 product on breast cancer cell lines. Surg Today 26: 501-507.
79. Kallioniemi O-P, Holli K, Visakorpi T, Koivula T, Helin HH, Isola JJ. 1991. Association of c-erb B-2 protein over-expression with high rate of cell proliferation, increased risk of visceral metastasis and poor long-term survival in breast cancer. Int J Cancer 49:650-655.
80. Karunagaran D, Tzahar E, Beerli RR, Chen XM, Graus-Porta D, Ratzkin BJ, Seger R, Hynes NE, Yarden Y. 1996. ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer. EMBO J 15:254-264.
81. neu receptor. Nat Med 1:644-648.
82. Kawakami Y, Eliyahu S, Jennings C, Sakaguchi K, Kang X, Southwood S, Robbins PF, Sette A, Appella E, Rosenberg SA. 1995. Recognition multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J Immunol 154:3961-3968.
83. Kim H-H, Sierke SL, Koland JG. 1994. Epidermal growth factor-dependent association of phosphatidylinositol 3-kinase with the erb B3 gene product. J Biol Chem 269:24747-24755.
84. King CR, Borrello I, Bellot F, Comoglio P, Schlessinger J. 1988. EGF binding to its receptor triggers a rapid tyrosine phosphorylation of the erbB-2 protein in the mammary tumor cell line SK-BR-3. EMBO J 7:1647-1651.
85. Kokai Y, Myers JN, Wada T, Brown VI, LeVea CM, Davis JG, Dobashi K, Greene MI. 1989. Synergistic interaction of p185c-neu and the EGF receptor leads to transformation of rodent fibroblasts. Cell 58:287-292.
86. Kraus MH, Issing W, Miki T, Popescu NC, Aaronson SA. 1989. Isolation and characterization of erbB3, a third member of the erbB/ epidermal growth factor receptor family: evidence for overexpression in a subset of human mammary tumors. Proc Natl Acad Sci USA 86:9193-9197.
87. Leitzel K, Teramoto Y, Konrad K, Chinchilli V M, Volas G, Grossberg H, Harvey H, Demers L, Lipton A. 1995. Elevated serum c-erb B-2 antigen levels and decreased response to hormone therapy of breast cancer. J Clin Oncol 13:1129-1135.
88. Leitzel K, Teramoto Y, Sampson E, Mauceri J, Langton BC, Demers L, Podczaski E, Harvey H, Shambaugh S, Volas G, Weaver S, Lipton A. 1992. Elevated soluble c-erbB-2 antigen levels in the serum and effusions of a proportion of breast cancer patients. J Clin Oncol 10:1436-1443.
89. Lenferink AE, Pinkas-Kramarski R, van de Poll ML, van Vugt MJ, Klapper LN, Tzahar E, Waterman H, Sela M, van Zoelen EJ, Yarden Y. 1998. Differential endocytic routing of homo- and heterodimeric ErbB tyrosine kinases confers signaling superiority to receptor heterodimers. EMBO J 17:3385-3397.
90. HER2 monoclonal antibodies. Cancer Immunol Immunother 37:255-263.
91. Liu Y, El-Ashry D, Chen D, Ding IYF, Kern FG. 1995. MCF-7 breast cancer cells overexpressing transfected c-erb B-2 have an in vitro growth advantage in estrogen-depleted conditions and reduced estrogen-dependence and tamoxifen-sensitivity in vivo. Breast Cancer Res Treat 34:97-117.
92. Lovekin C, Ellis IO, Locker A, Robertson JFR, Bell J, Nicholson R, Gullick WJ, Elston CW, Blamey RW. 1991. c-erbB-2 oncoprotein expression in primary and advanced breast cancer. Br J Cancer 63:439-443.
93. Maia DM. 1999. Immunohistochemical assays for HER2 overexpression. J Clin Oncol 17:1650.
94. Marks J R, Humphrey P A, Wu K, Berry D, Bandarenko N, Kerns B-J M, Iglehart J D. 1994. Overexpression of p53 and HER-2/neu proteins as prognostic markers in early stage breast cancer. Ann Surg 219:332-341.
95. Marshall C J. 1995. Specificity of receptor tirosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation. Cell 80:179-185.
96. Matsuda S, Kadowaki Y, Ichino M, Akiyama T, Toyoshima K, Yamamoto T. 1993. 17β-Estradiol mimics ligand activity of the c-erbB2 protooncogene product. Proc Natl Acad Sci USA 90:10803-10807.
97. McCann AH, Dervan PA, O'Regan M, Codd MB, Gullick WJ, Tobin BMJ, Carney DN. 1991. Prognostic significance of c-erbB-2 and estrogen receptor status in human breast cancer. Cancer Res 51: 3296-3303.
98. Ménard S, Pupa S M, Casalini P, Rilke F, Colnaghi MI. 1996. Relationship of histological grade, c-erbB-2 expression and inflammatory infiltrate to prognosis in carcinoma of the breast: in reply. J Clin Oncol 14:2407.
99. Ménard S, Valagussa P, Pilotti S, Biganzoli E, Boracchi P, Tomasic G, Casalini P, Marubini E, Colnaghi M I, Cascinelli N, Bonadonna G. 1999. HER2 Overexpression and response to CMF in lymph node-positive breast cancer. Proc ASCO 18:69a.
100. Molina R, Ciocca DR, Tandon AK, Allred DC, Clark GM, Chamness GC, Gullick WJ, McGuire WL. 1992. Expression of HER-2/neu oncoprotein in human breast cancer: A comparison of immunohistochemical and Western blot techniques. Anticancer Res 12:1965-1971.
101. Muss HB, Thor AD, Berry DA, Kute T, Liu ET, Koerner F, Cirrincione CT, Budman DR, Wood WC, Barcos M, Henderson IC. 1994. c-erb B-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 330:1260-1266.
102. Nicholson RI, McClelland RA, Gee JMW, Manning DL, Cannon P, Robertson JFR, Ellis IO, Blamey RW. 1994. Epidermal growth factor receptor expression in breast cancer: association with response to endocrine therapy. Breast Cancer Res Treat 29:117-125.
103. Noguchi M, Koyasaki N, Ohta N, Kitagawa H, Earashi M, Thomas M, Miyazaki I, Mizukami Y. 1992. C-erb B-2 oncoprotein expression versus internal mammary lymph node metastases as additional prognostic factors in patients with axillary lymph node-positive breast cancer. Cancer 69:2953-2960.
104. Noh DY, Kang HS, Kim YC, Youn YK, Oh SK, Choe KJ, Park IA, Ryu SH, Suh PG. 1998. Expression of phospholipase C-gamma 1 and its transcriptional regulators in breast cancer tissues. Anticancer Res 18:2643-2648.
105. O'Malley FP, Saad Z, Kerkvliet N, Doig G, Stitt L, Ainsworth P, Hundal H, Chambers AF, Turnbull DI, Bramwell V. 1996. The predictive power of semiquantitative immunohistochemical assessment of p53 and c-erb B-2 in lymph node-negative breast cancer. Hum Pathol 27:955-963.
106. O'Reilly SM, Barnes DM, Camplejohn RS, Bartkova J, Gregory WM, Richards MA. 1991. The relationship between c-erb B-2 expression, S-phase fraction and prognosis in breast cancer. Br J Cancer 63: 444-446.
107. Paik S, Bryant J, Park C, Fisher B, Tan-Chiu E, Hyams D, Fisher ER, Lippman ME, Wickerham D L, Wolmark N. 1998. erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J Natl Cancer Inst 90: 1361-1370.
108. Paik S, Hazan R, Fisher ER, Sass RE, Fisher B, Redmond C, Schlessinger J, Lippman ME, King CR. 1990. Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer. J Clin Oncol 8:103-112.
109. Paterson MC, Dietrich KD, Danyluk J, Paterson AHG, Lees AW, Jamil N, Hanson J, Jenkins H, Krause BE, Mcblain WA, Slamon DJ, Fourney RM. 1991. Correlation between C-erbB-2 amplification and risk of recurrent disease in node-negative breast cancer. Cancer Res 51:556-567.
110. Pauletti G, Godolphin W, Press MF, Slamon DJ. 1996. Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. Oncogene 13:63-72.
111. Pavy JJ, Descotes F, Adessi GL. 1993. HER-2/neu oncogene: what does amplification mean. Br J Cancer 68:214-215.
112. Pegram M, Hsu S, Lewis G, Pietras R, Beryt M, Sliwkowski M, Coombs D, Baly D, Kabbinavar F, Slamon D. 1999. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene 18:2241-2251.
113. Pegram MD, Lipton A, Hayes DF, Weber BL, Baselga JM, Tripathy D, Baly D, Baughman SA, Twaddell T, Glaspy JA, Slamon DJ. 1998. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 16:2659-2671.
114. Peles E, Levy RB, Or E, Ullrich A, Yarden Y. 1991. Oncogenic forms of the neu/HER2 tyrosine kinase are permanently coupled to phospholipase C gamma. EMBO J 10:2077-2086.
115. Penault-Llorca F, Adelaïde J, Houvenaeghel G, Hassoun J, Birnbaum D, Jacquemier J. 1994. Optimization of immunohistochemical detection of ERBB2 in human breast cancer: impact of fixation. J Pathol 173:65-75.
116. Peoples GE, Goedegebuure PS, Smith R, Linehan DC, Yoshino I, Eberlein TJ. 1995. Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide. Proc Natl Acad Sci USA 92:432-436.
117. Pinkas-Kramarski R, Soussan L, Waterman H, Levkowitz G, Alroy I, Klapper L, Lavi S, Seger R, Ratzkin BJ, Sela M, Yarden Y. 1996. Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. EMBO J 15:2452-2467.
118. erbB4, a fourth member of the epidermal growth factor receptor family. Proc Natl Acad Sci USA 90:1746-1750.
119. Press MF, Bernstein L, Thomas PA, Meisner LF, Zhou JY, Ma YL, Hung G, Robinson RA, Harris C, El-Naggar A, Slamon DJ, Phillips RN, Ross JS, Wolman SR, Flom KJ. 1997. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. J Clin Oncol 15: 2894-2904.
120. Press MF, Pike MC, Chazin VR, Hung G, Udove JA, Markowicz M, Danyluk J, Godolphin W, Sliwkowski M, Akita R, Paterson MC, Slamon DJ. 1993. Her-2/neu expression in node-negative breast cancer: Direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease. Cancer Res 53:4960-4970.
121. Pupa SM, Bufalino R, Invernizzi AM, Andreola S, Rilke F, Lombardi L, Colnaghi M I, Ménard S. 1996. Macrophage infiltrate and prognosis in c-erb B-2-overexpressing breast carcinomas. J Clin Oncol 14:85-94.
122. Pupa SM, Ménard S, Andreola S, Colnaghi MI. 1993a. Antibody response against the c-erbB-2 oncoprotein in breast carcinoma patients. Cancer Res 53:5864-5866.
123. Pupa SM, Ménard S, Morelli D, Pozzi B, De Palo G, Colnaghi MI. 1993b. The extracellular domain of the c-erbB-2 oncoprotein is released from tumor cells by proteolytic cleavage. Oncogene 8:2917-2923.
124. c-neu and epidermal growth factor receptor associate into a structure composed of activated kinases. Proc Natl Acad Sci USA 89:1330-1334.
125. Quenel N, Wafflart J, Bonichon F, de Mascarel I, Trojani M, Durand M, Avril A, Coindre JM. 1995. The prognostic value of c-erbB2 in primary breast carcinomas: a study on 942 cases. Breast Cancer Res Treat 35:283-291.
126. Rilke F, Colnaghi MI, Cascinelli N, Andreola S, Baldini MT, Bufalino R, Della Porta G, Ménard S, Pierotti MA, Testori A. 1991. Prognostic significance of HER-2/neu expression in breast cancer and its relationship to other prognostic factors. Int J Cancer 49:44-49.
127. Roche PC, Ingle JN. 1999. Increased HER2 with U.S. food and drug administration-approved antibody. J Clin Oncol 17:434-435.
128. Rosen PP, Lesser ML, Arroyo CD, Cranor M, Borgen P, Norton L. 1995. Immunohistochemical detection of HER2/neu in patients with axillary lymph node negative breast carcinoma: a study of epidemiologic risk factors, histologic features, and prognosis. Cancer 75:1320-1326.
129. Ross JS, Fletcher JA. 1999. HER-2/neu (c-erb-B2) gene and protein in breast cancer. Am J Clin Pathol 112:853-67
130. Ross JS, Muraca PJ, Jaffe D. 1998. Multivariate analysis of prognostic factors in lymph node negative breast cancer. Mod Pathol 11:26a.
131. Rowinsky EK, Donehower RC. 1995. Paclitaxel (taxol). N Engl J Med 332:1004-1014.
132. Sauter G, Feichter G, Torhorst J, Moch H, Novotna H, Wagner U, Durmuller U, Waldman FM. 1996. Fluorescence in situ hybridization for detecting erbB-2 amplification in breast tumor fine needle aspiration biopsies. Acta Cytol 40:164-173.
133. Schimmelpenning H, Eriksson ET, Falkmer UG, Rutqvist LE, Johansson H, Fallenius A, Auer GU. 1992. Prognostic significance of immunohistochemical c-erbB-2 proto-oncogene expression and nuclear DNA content in human breast cancer. Eur J Surg Oncol 18:530-537.
134. Schonborn I, Zschiesche W, Spitzer E, Minguillon C, Mohner M, Ebeling K, Grosse R. 1994. C-erbB2-overexpression in primary breast cancer: independent prognostic factor in patients at high risk. Breast Cancer Res Treat 29:287-295.
135. Scott GK, Dodson JM, Montgomery PA, Johnson RM, Sarup JC, Wong WL, Ullrich A, Shepard HM, Benz CC. 1991. p185HER2 signal transduction in breast cancer cells. J Biol Chem 266:14300-14305.
136. Seshadri R, Firgaira FA, Horsfall DJ, McCaul K, Setlur V, Kitchen P. 1993. Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. J Clin Oncol 11:1936-1942.
137. Seshadri R, Mathews C, Dobrovic A, Horsfall D J. 1989. The significance of oncogene amplification in primary breast cancer. Int J Cancer 43:270-272.
138. Shalaby MR, Carter P, Maneval D, Giltinan D, Kotts C. 1995. Bispecific HER2 × CD3 antibodies enhance T-cell cytotoxicity in vitro and localize to HER2-overexpressing xenografts in nude mice. Clin Immunol Immunopathol 74:185-192.
139. Shepard HM, Lewis GD, Sarup JC, Fendly BM, Maneval D, Mordenti J, Figari I, Kotts CE, Palladino MAJ, Ullrich A. 1991. Monoclonal antibody therapy of human cancer: taking the HER2 protooncogene to the clinic. J Clin Immunol 11:117-127.
140. Slamon D, Leyland-Jones B, Shank S. 1998. Addition of Herceptin (humanized anti-HER2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer (HER2+/MBC) markedly increases anticancer activity: a randomized, multinational controlled phase III trial. Proc Am Soc Clin Oncol 17:98a.
141. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. 1987. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177-182.
142. Stern DF, Heffernan PA, Weinberg RA. 1986. p185, a product of the neu proto-oncogene, is a receptorlike protein associated with tyrosine kinase activity. Mol Cell Biol 6:1729-1740.
143. Stern DF, Kamps MP, Cao H. 1988. Oncogenic activation of p185neu stimulates tyrosine phosphorylation in vivo. Mol Cell Biol 8:3969-3973.
144. Stockmeyer B, Valerius T, Repp R, Heijnen IAFM, Buhring H-J, Deo YM, Kalden JR, Gramatzki M, Van de Winkel JGJ. 1997. Preclinical studies with FcgR bispecific antibodies and granulocyte colony-stimulating factor-primed neutrophils as effector cells against HER-2/neu overexpressing breast cancer. Cancer Res 57:696-701.
145. Sundblad AS, Pellicer EM, Ricci L. 1996. Carcinoembryonic antigen expression in stages I and II breast cancer: its relationship with clinicopathologic factors. Hum Pathol 27:297-301.
146. Tagliabue E, Ardini E, Pellegrini R, Campiglio M, Bufalino R, Jeschke M, Groner B, Colnaghi MI, Ménard S. 1996. Laminin activates the p185HER2 oncoprotein and mediates growth inhibition of breast carcinoma cells. Br J Cancer 74:1427-1433.
147. Tetu B, Brisson J. 1994. Prognostic significance of HER-2/neu oncoprotein expression in node-positive breast cancer. Cancer 73:2359-2365.
148. Thor AD, Berry DA, Budman DR, Muss HB, Kute T, Henderson IC, Barcos M, Cirrincione C, Edgerton S, Allred C, Norton L, Liu ET. 1998. erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. J Natl Cancer Inst 90:1346-1360.
149. Tiwari RK, Borgen PI, Wong GY, Cordon-Cardo C, Osborne MP. 1992. HER-2/neu amplification and overexpression in primary human breast cancer is associated with early metastasis. Anticancer Res 12:419-426.
150. Toikkanen S, Helin H, Isola J, Joensuu H. 1992. Prognostic significance of HER-2 oncoprotein expression in breast cancer: a 30-year follow-up. J Clin
151. Toikkanen S, Joensuu H. 1992. HER-2/neu oncoprotein as a prognostic factor in breast cancer. J Clin Oncol 10:1817.
152. Toyoda H, Komurasaki T, Ikeda Y, Yoshimoto M, Morimoto S. 1998. Molecular cloning of mouse epiregulin, a novel epidermal growth factor-related protein expressed in the early stage of development. FEBS Lett 377:403-407.
153. Tsuda H, Hirohashi S, Shimosato Y, Hirota T, Tsugane S, Watanabe S, Terada M, Yamamoto H. 1990. Correlation between histologic grade of malignancy and copy number of c-erbB-2 gene in breast carcinoma. Cancer 65:1794-1800.
154. Tzahar E, Pinkas-Kramarski R, Moyer J D, Kapper L N, Alroy I, Levkowitz G, Shelly M, Henis S, Eisenstein M, Ratzkin B J, Sela M, Andrews G C, Yarden Y. 1997. Bivalence of EGF-like ligands drives the ErbB signaling network. EMBO J 16:4938-4950.
155. Tzahar E, Waterman H, Chen X, Levkowitz G, Karunagaran D, Lavi S, Ratzkin BJ, Yarden Y. 1996. A hierarchinal network of interreceptor interactions determines signal transduction by neu differentiation factor/neuregulin and epidermal growth factor. Mol Cell Biol 16:5276-5287.
156. Tzahar E, Yarden Y. 1998. The ErbB-2/HER2 oncogenic receptor of adenocarcinomas: from orphanhood to multiple stromal ligands. Biochim Biophys Acta 1377:M25-M37
157. Valone FH, Kaufman PA, Guyre PM, Lewis LD, Memoli V, Deo Y, Graziano R, Fisher JL, Meyer L, Mrozek-Orlowski M, Wardwell K, Guyre V, Morley TL, Arvizu C, Fanger MW. 1995. Phase Ia/Ib trial of bispecific antibody MDX-210 in patients with advanced breast or ovarian cancer that overexpresses the proto-oncogene HER-2/neu. J Clin Oncol 13:2281-2292.
158. Van de Vijver MJ, Peterse JL, Mooi WJ, Wisman P, Lomans J, Dalesio O, Nusse R. 1988. Neu-protein over-expression in breast cancer. Asoociation with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. N Engl J Med 319:1239-1245.
159. Wada T, Qian X, Greene MI. 1990. Intermolecular association of the p185neu protein and EGF receptor modulates EGF receptor function. Cell 61:1339-1347.
160. Watanabe T, Fukutomi T, Tsuda H, Adachi I, Nanasawa T, Yamamoto H, Abe K. 1993. Determination of c-erbB-2 protein in primary breast cancer tissue extract using an enzyme immunoassay. Jpn J Cancer Res 84:1279-1286.
161. Waterman H, Sabanai I, Geiger B, Yarden Y. 1998. Alternative intracellular routing of ErbB receptors may determine signaling potency. J Biol Chem 273:13819-13827.
162. Weiner LM, Clark JI, Davey M, Li WS, Garcia de Palazzo I, Ring DB, Alpaugh RK. 1995. Phase I trial of 2B1, a bispecific monoclonal antibody targeting c-erbB-2 and Fc gammaRIII. Cancer Res 55: 4586-4593.
163. Weiss A, Schlessinger J. 1998. Switching signals on or off by receptor dimerization. Cell 94:277-280.
164. Wen D, Peles E, Cupples R, Suggs SV, Bacus SS, Luo Y, Trail G, Hu S, Silbiger SM, Ben Levy R, Koski RA, Lu HS, Yarden Y. 1992. Neu differentiation factor: a transmembrane glycoprotein containing an EGF domain and an immunoglobulin homology unit. Cell 69:559-572.
165. Winstanley J, Cooke T, Murray GD, Platt-Higgins A, George WD, Holt S, Myskov M, Spedding A, Barraclough BR, Rudland PS. 1991. The long term prognostic significance of c-erb B-2 in primary breast cancer. Br J Cancer 63:447-450.
166. Wright C, Angus B, Nicholson S, Sinsbury JRC, Cairns J, Gullick W, Kelly P, Harris A, Horme W. 1989b. Expression of c erb B-2 oncoprotein: a prognostic indicator in human breast cancer. Cancer Res 49:2087-2090.
167. Wright C, Nicholson S, Angus B, Cairns J, Sainsbury JRC, Gullick WJ, Harris AL, Home CHW. 1989a. Association of c-erbB-2 onco-protein expression with lack of response to endocrine therapy in recurrent breast-cancer. J Pathol 158:350.
168. Wright C, Nicholson S, Angus B, Sainsbury JRC, Farndon J, Cairns J, Harris AL, Home CHW. 1992. Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer. Br J Cancer 65:118-121.
169. Wright M, Grim J, Deshane J, Kim M, Strong TV, Siegal GP, Curiel DT. 1997. An intracellular anti-erbB-2 single-chain antibody is specifically cytotoxic to human breast carcinoma cells overexpressing erbB-2. Gene Ther 4:317-322.
170. Wurmser AE, Gary JD, Emr SD. 1999. Phosphoinositide 3-kinases and their FYVE domain-containing effectors as regulators of vacuolar/lysosomal membrane trafficking pathways. J Biol Chem 274: 9129-9132.
171. Xing WR, Gilchrist KW, Harris CP, Samson W, Meisner LF. 1996. FISH detection of HER-2/neu oncogene amplification in early onset breast cancer. Breast Cancer Res Treat 39:203-212.
172. Yamashita J, Ogawa M, Sakai K. 1995. Prognostic significance of three novel biologic factors in a clinical trial of adjuvant therapy for node-negative breast cancer. Surgery 117:601-608.
173. Yoshino I, Goedegebuure PS, Peoples GE, Parikh AS, DiMaio JM, Lyerly HK, Gazdar AF, Eberlein TJ. 1994. HER2/neu-derived peptides are shared antigens among human non-small cell lung cancer and ovarian cancer. Cancer Res 54:3387-3390.
174. Yu D, Jing T, Liu B, Yao J, Tan M, McDonnell TJ, Hung MC. 1998. Overexpression of ErbB2 blocks Taxol-induced apoptosis by upregulation of p21Cip1, which inhibits p34Cdc2 kinase. Mol Cell 2:581-591.
175. Yu D, Wang SS, Dulski KM, Tsai CM, Nicolson GL, Hung MC. 1994. c-erb B-2/neu overexpression enhances metastatic potential of human lung cancer cells by induction of metastasis-associated properties. Cancer Res 54:3260-3266.
176. Yusa K, Sugimoto Y, Yamori T, Yamamoto T, Toyoshima K, Tsuruo T. 1990. Low metastatic potential of clone from murine colon adenocarcinoma-26 increased by transfection of activated c-erbB-2 gene. J Natl Cancer Inst 82:1633-1636.
177. Zhang D, Sliwkowski MX, Mark M, Frantz G, Akita R, Sun Y, Hillan K, Crowley C, Brush J, Godowski PJ. 1997. Neuregulin-3 (NRG3): a novel neural tissue-enriched protein that binds and activates ErbB4. Proc Natl Acad Sci USA 94:9562-9567.
178. Zhang L, Hung MC. 1996. Sensitization of HER-2/neu -overexpressing non-small cell lung cancer cells to chemotherapeutic drugs by tyrosine kinase inhibitor emodin. Oncogene 12:571-576.
179. Zhang L, Lau YK, Xia W, Hortobagyi GN, Hunh MC. 1999. Tyrosine kinase inhibitor emodin suppresses growth of HER2/neu-overexpressing breast cancer cells in athymic mice and sensitizes these cells to the inhibitory effect of paclitaxel. Clin Cancer Res 5:343-353.
180. Zhang LS, Chang CJ, Bacus SS, Hung M-C. 1995. Suppressed transformation and induced differentiation of HER-2 neu-overexpressing breast cancer cells by emodin. Cancer Res 55:3890-3896.
181. HER2 overexpressing tumor cells. Int J Cancer 62: 319-324.